At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 2 enrolled
Drug / intervention
TRC105 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Patient Treatment Protocol of TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma
In Brief
A Phase 2 clinical trial evaluating TRC105 and Bevacizumab for Choriocarcinoma. Completed, enrolled 2 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether TRC105 in combination with Bevacizumab is effective in the treatment of two patients with metastatic and refractory choriocarcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChoriocarcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
First PostedMar 2015
Primary CompletionDec 2017
TodayJul 2026
First PostedMar 24, 2015
Enrollment StartJan 1, 2015
Primary CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 11.3 years ago
Interventions
TRC105biological
weekly i.v. TRC105 in combination with every 2 weeks i.v.bevacizumab, until progression or unacceptable toxicity develops
Bevacizumabbiological
Every 2 weeks i.v.bevacizumab in combination with weekly i.v. TRC105, until progression or unacceptable toxicity develops